替尔泊肽：难治性高血压治疗新突破？一例成功案例引发热议

Core Insights - The article discusses the challenges and new perspectives in the treatment of resistant hypertension, particularly focusing on the potential of GLP-1/GIP receptor agonists in managing blood pressure in patients who do not respond to traditional medications [6][7][12]. Group 1: Resistant Hypertension - Resistant hypertension is defined as a condition where patients cannot achieve effective blood pressure control despite using five or more antihypertensive medications at maximum doses [6]. - This condition significantly increases the risk of cardiovascular and renal complications, highlighting the need for more effective treatment options [6]. Group 2: Case Study - A case study of a 71-year-old female patient illustrates the potential of GLP-1/GIP receptor agonists. Despite being on eight antihypertensive medications, her blood pressure remained uncontrolled until she began treatment with liraglutide in 2013, which reduced her systolic blood pressure from 206 mmHg to 160 mmHg over six years [8][10]. - The treatment was later switched to dulaglutide and then to terzepatide, resulting in further blood pressure reduction to 135 mmHg, demonstrating the effectiveness of these agents in resistant hypertension [9][10]. Group 3: Mechanism of Action - GLP-1/GIP receptors are widely distributed in the hypothalamus, carotid body, vascular endothelium, and kidneys. Animal studies suggest that these receptor agonists may lower blood pressure by inhibiting sympathetic nervous system activity, improving endothelial dysfunction, and/or reducing vascular remodeling [12]. - The findings from the case study indicate that GLP-1/GIP receptor agonists may have broader applications in blood pressure control, especially for patients with resistant hypertension, and emphasize the need for further exploration of their mechanisms [12].